Healthcare professionals

Empower stem cell transplantation for your AML patients

The CliniMACS® CD34 Reagent System is an FDA-approved method to deplete T cells as an effective means of GVHD prophylaxis in patients with AML undergoing allogeneic stem cell transplantation in 1st complete remission.

See the data and learn about the CliniMACS CD34 Reagent System.

Product categories

Background information

Stem cell transplantation in AML

Once diagnosed, the survival rate of patients with acute myeloid leukemia (AML) is low: Two-thirds of young adults and 90% of older adults still die of their disease and its sequelae. 
Read more

Clinical data

The CliniMACS® CD34 Reagent System was tested in a phase II single-arm multicenter study with a total of 44 patients in first or second morphologic complete remission.
Read more

Downloads and references

Supportive documents and downloads
Read more

Contact information for healthcare professionals

Read more
Matching products:

Miltenyi Biotec Norden AB
phone:
fax:
macs@miltenyibiotec.se